Home / Health / SMA Screening: Hope for Some, But What About Others?
SMA Screening: Hope for Some, But What About Others?
21 Jul
Summary
- Newborn screening for SMA will begin in England in 2027.
- Duchenne muscular dystrophy affects around 100 boys annually.
- Families report years of uncertainty and delayed diagnoses for DMD.
Starting in 2027, England will implement newborn screening for spinal muscular atrophy (SMA). This initiative is a significant advancement, enabling earlier diagnosis and access to treatment, thereby improving outcomes for affected children and providing crucial clarity for families.
The introduction of SMA screening prompts a critical question: why are other severe genetic conditions, such as Duchenne muscular dystrophy (DMD), not yet included in newborn screening programs? DMD impacts approximately 100 boys each year, causing progressive muscle weakness.
Research and advocacy groups, like Duchenne UK, have documented the extensive challenges families face, including prolonged diagnostic journeys involving numerous GP visits and years of uncertainty. Timely diagnosis for DMD is vital for accessing emerging treatments and specialized support.
Beyond treatment access, newborn screening aids families in future planning and securing necessary services. Campaigners' efforts in securing SMA screening serve as a catalyst for broader discussions on rare genetic conditions and the persistent barriers faced by families seeking timely support.
